You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 8, August 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Erythromycin-Sulfisoxazole vs Amoxicillin in the Treatment of Acute Otitis Media in Children

A Double-blind, Multiple-Dose Comparative Study

William J. Rodriguez, MD, PhD; Richard H. Schwartz, MD; Tahir Sait, MD; Waheed N. Khan, PhD; Om P. Chhabra, MD; Margan J. Chang, MD; Soma Reddy, MD; Lloyd A. Marks, MD; A. Jack Gold, MD

Am J Dis Child. 1985;139(8):766-770.


Abstract

• A fixed combination of erythromycin ethylsuccinate and sulfisoxazole acetyl (erythromycin-sulfa) was compared with amoxicillin for the treatment of acute otitis media (AOM) in children. Of 145 patients studied, 76 boys and 69 girls were compliant and were evaluated for drug efficacy (72 amoxicillin, 73 erythromycin-sulfa). Based on otoscopic and tympanometric results, cure rates at ten to 14 days for AOM due to all organisms were 83% (63/72) for amoxicillin and 89% (65/73) for erythromycinsulfa; for Haemophilus species (including mixed infections), they were 84% for amoxicillin (26/31) and 83% for erythromycin-sulfa (20/14). Cure rates for ampicillin-resistant Haemophilus were 1/1 for amoxicillin and 7/8 (88%) for erythromycin-sulfa; one patient (12%) had persistent AOM at day 10. Of the patients with AOM due to Streptococcus pneumoniae, 82% (29/35) in the amoxicillin-treated group and 98% (39/40) in the erythromycin-sulfa–treated group were cured. Patients with S pneumoniae as the initial infecting organism who were treated with amoxicillin had significantly more clinical recurrences then their erythromycin-sulfa–treated counterparts, 66% (8/12) vs 33% (3/9). There was no difference between treatment groups in recurrence rates for patients with Haemophilus as the initial infecting organism. On the treatment day indicated, the following number of patients had middle ear effusion: by days 10 to 14, 38% (27/72) amoxicillin-treated patients and 48% (35/73) erythromycin-sulfa–treated patients; by day 28,10% (7/71) amoxicillin-treated patients and 16% (11/70) erythromycin-sulfa–treated patients. There were no significant differences in adverse reactions. The erythromycin-sulfa combination is safe and effective treatment for AOM, including ampicillin-resistant Haemophilus.

(AJDC 1985;139:766-770)



Author Affiliations

From the Department of Infectious Diseases and Microbiology Research, Children's Hospital National Medical Center (Drs Rodriguez, Khan, Chang, and Marks) and the Department of Child Health and Development, George Washington University School of Medicine (Drs Rodriguez, Schwartz, and Chang), Washington, DC. Dr Schwartz is also in private practice in Vienna, Va; Drs Sait, Chhabra, and Reddy are in private practice in Waldorf, Md. Dr Gold is with Ross Laboratories, Columbus, Ohio.


Footnotes

Reprint requests to 111 Michigan Ave NW, Washington, DC 20010 (Dr Rodriguez).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Otitis Media: A Review
Liston
CLIN PEDIATR 1995;34:542-548.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.